Paysign, Inc. (NASDAQ:PAYS) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its stake in shares of Paysign, Inc. (NASDAQ:PAYS - Free Report) by 11.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,501,622 shares of the company's stock after buying an additional 149,200 shares during the period. Renaissance Technologies LLC owned approximately 2.80% of Paysign worth $4,535,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Paysign by 327.4% in the third quarter. Barclays PLC now owns 47,090 shares of the company's stock valued at $173,000 after acquiring an additional 36,071 shares during the period. Sanctuary Advisors LLC increased its stake in Paysign by 4.3% in the third quarter. Sanctuary Advisors LLC now owns 121,089 shares of the company's stock worth $419,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. lifted its holdings in Paysign by 164.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 63,247 shares of the company's stock valued at $232,000 after buying an additional 39,299 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Paysign by 33.5% in the fourth quarter. SG Americas Securities LLC now owns 15,508 shares of the company's stock valued at $47,000 after purchasing an additional 3,895 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Paysign by 13.7% in the 4th quarter. Rhumbline Advisers now owns 44,284 shares of the company's stock worth $134,000 after buying an additional 5,339 shares during the period. 25.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Mark Newcomer sold 100,000 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $2.73, for a total value of $273,000.00. Following the sale, the chief executive officer now directly owns 8,936,886 shares of the company's stock, valued at $24,397,698.78. This represents a 1.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 22.40% of the company's stock.

Paysign Stock Down 5.4 %

Shares of Paysign stock traded down $0.13 during midday trading on Friday, hitting $2.28. The company had a trading volume of 141,214 shares, compared to its average volume of 208,413. The stock has a market cap of $122.55 million, a price-to-earnings ratio of 15.20 and a beta of 0.77. Paysign, Inc. has a 12-month low of $1.80 and a 12-month high of $5.59. The company has a fifty day simple moving average of $2.33 and a 200 day simple moving average of $2.93.

Paysign (NASDAQ:PAYS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Paysign had a net margin of 14.28% and a return on equity of 30.64%. The business had revenue of $15.61 million during the quarter, compared to the consensus estimate of $15.42 million. As a group, analysts expect that Paysign, Inc. will post 0.21 EPS for the current year.

Analyst Ratings Changes

PAYS has been the subject of several recent research reports. Barrington Research restated an "outperform" rating and issued a $7.00 price target on shares of Paysign in a report on Wednesday, March 26th. DA Davidson restated a "buy" rating and issued a $6.00 target price on shares of Paysign in a research note on Wednesday, March 26th.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.